๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ An ๐“ฒ๐“ท๐“ฒ๐“ฝ๐“ฒ๐“ช๐“ฝ๐“ฒ๐“ฟ๐“ฎ that encourages ๐•‹๐”ผ๐”ธ๐•„๐•Ž๐•†โ„๐•‚ towards ยซscience, education and technologyยป.

๐๐ฅ๐จ๐จ๐ ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž ๐š๐Ÿ๐ญ๐ž๐ซ ๐œ๐ก๐š๐ง๐ ๐ž๐ฌ ๐ข๐ง ๐š๐ฅ๐œ๐จ๐ก๐จ๐ฅ ๐œ๐จ๐ง๐ฌ๐ฎ๐ฆ๐ฉ๐ญ๐ข๐จ๐ง ๐Ÿ๐ซ๐จ๐ฆ ๐ฆ๐ข๐ฅ๐ ๐ญ๐จ ๐ฆ๐จ๐๐ž๐ซ๐š๐ญ๐ž ๐ข๐ง ๐ฐ๐จ๐ฆ๐ž๐ง ๐š๐ง๐ ๐ฆ๐ž๐ง In conclusion, even at low le...
18/06/2026

๐๐ฅ๐จ๐จ๐ ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž ๐š๐Ÿ๐ญ๐ž๐ซ ๐œ๐ก๐š๐ง๐ ๐ž๐ฌ ๐ข๐ง ๐š๐ฅ๐œ๐จ๐ก๐จ๐ฅ ๐œ๐จ๐ง๐ฌ๐ฎ๐ฆ๐ฉ๐ญ๐ข๐จ๐ง ๐Ÿ๐ซ๐จ๐ฆ ๐ฆ๐ข๐ฅ๐ ๐ญ๐จ ๐ฆ๐จ๐๐ž๐ซ๐š๐ญ๐ž ๐ข๐ง ๐ฐ๐จ๐ฆ๐ž๐ง ๐š๐ง๐ ๐ฆ๐ž๐ง
In conclusion, even at low levels, alcohol consumption was associated with higher blood pressure, and abstinence was associated with lower blood pressure in both sexes. These findings suggest that abstaining from alcohol is a widely applicable strategy, even among light to moderate drinkers, for blood pressure control. In this large dataset, changes in blood pressure in women associated with consumption as low as 0.5 to 1 drink per day can be detected.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Suzuki T, Fukui S, Yoneoka D, et al. Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. JACC; 86:(21)
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

๐๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐ญ๐ซ๐š๐ฌ ๐œ๐š๐ฆ๐›๐ข๐จ๐ฌ ๐ž๐ง ๐ž๐ฅ ๐œ๐จ๐ง๐ฌ๐ฎ๐ฆ๐จ ๐๐ž ๐š๐ฅ๐œ๐จ๐ก๐จ๐ฅ ๐๐ž ๐ฅ๐ž๐ฏ๐ž ๐š ๐ฆ๐จ๐๐ž๐ซ๐š๐๐จ ๐ž๐ง ๐ฆ๐ฎ๐ฃ๐ž๐ซ๐ž๐ฌ ๐ฒ ๐ก๐จ๐ฆ๐›๐ซ๐ž๐ฌ En conclusiรณn, incluso en...
18/06/2026

๐๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐ญ๐ซ๐š๐ฌ ๐œ๐š๐ฆ๐›๐ข๐จ๐ฌ ๐ž๐ง ๐ž๐ฅ ๐œ๐จ๐ง๐ฌ๐ฎ๐ฆ๐จ ๐๐ž ๐š๐ฅ๐œ๐จ๐ก๐จ๐ฅ ๐๐ž ๐ฅ๐ž๐ฏ๐ž ๐š ๐ฆ๐จ๐๐ž๐ซ๐š๐๐จ ๐ž๐ง ๐ฆ๐ฎ๐ฃ๐ž๐ซ๐ž๐ฌ ๐ฒ ๐ก๐จ๐ฆ๐›๐ซ๐ž๐ฌ
En conclusiรณn, incluso en niveles bajos, el consumo de alcohol se asociรณ con una PA mรกs alta, y el abandono del consumo se asociรณ con una PA mรกs baja en ambos sexos. Estos hallazgos sugieren que el abandono del consumo de alcohol es una estrategia ampliamente aplicable, incluso entre bebedores de leves a moderados, para el control de la PA. En este amplio conjunto de datos, se pueden detectar cambios en la PA en mujeres asociados con el consumo a niveles tan bajos como 0.5 a 1 bebida al dรญa .

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Suzuki T, Fukui S, Yoneoka D, et al. Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. JACC; 86:(21)
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

"๐—๐จ๐ฎ๐ซ๐ง๐š๐ฅ ๐—ฅ๐ž๐ฏ๐ข๐ž๐ฐ (๐‰๐‘)----------------------------------------------Performed on: Monday, April 27, 2026 at 18:00:36 in BE...
18/06/2026

"๐—๐จ๐ฎ๐ซ๐ง๐š๐ฅ ๐—ฅ๐ž๐ฏ๐ข๐ž๐ฐ (๐‰๐‘)
----------------------------------------------
Performed on: Monday, April 27, 2026 at 18:00:36 in BE
๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐‚๐‚ - ๐‘๐ž๐œ๐จ๐ง๐ฌ๐ข๐๐ž๐ซ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฎ๐ซ๐ž๐š-๐ญ๐จ-๐œ๐ซ๐ž๐š๐ญ๐ข๐ง๐ข๐ง๐ž ๐ซ๐š๐ญ๐ข๐จ ๐š๐ฌ ๐š ๐ฌ๐ข๐ ๐ง๐š๐ฅ ๐จ๐Ÿ ๐ฆ๐ฎ๐ฌ๐œ๐ฅ๐ž ๐œ๐š๐ญ๐š๐›๐จ๐ฅ๐ข๐ฌ๐ฆ ๐ข๐ง ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐œ๐ข๐ซ๐ซ๐ก๐จ๐ฌ๐ข๐ฌ (๐Ž๐ฎ๐ฌ๐ฌ๐š๐ฅ๐š๐ก) (๐ฆ๐š).๐ฉ๐๐Ÿ

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)

1. UREA issues
1. Portal hypertension โž• hepatocelualr DYS โ–ถ๏ธŽ alter N METABOLISM (โ†“UREAGENESIS efficiency)
2. Ammonia (intestines) โ†’ urea (water-soluble, excreted in the urine) โ–ถ๏ธŽ โ—ธ
1. Both are indicators of the same pathway
2. They reflect urea-cycle efficiency
3. Cirrhosis **perturbs** this pathway:
1. โ†‘ vascular R โž• portosystemic shunts ๐ŸŸฐ imp โ—ธ clearance โžฉ โ†‘ ammonia (systemically)
2. imp hepatocellular function ๐ŸŸฐ โ†“ urea-cycle โžฉ โ†“ urea (for a given N load)
4. Combined effect โ–ถ๏ธŽ โ†‘ ammonia โž• โ†“ urea
5. CLINICALLY โ–ถ๏ธŽ pxs have โ†“ โŒ„ โ€œnormalโ€ UCR โžฉ limited โ—ธ capacity to convert ammonia to urea.
6. AUR > 1,53 mg/g โ†” portal hypertension
1. Complications can modify it.
2. giBLEED (e.g. variceal) โžฉ ยซโ†‘N load โ†’ portal โญ•๏ธยป due to ๐Ÿซƒ๐ŸฝHb โ€œdigestion + reabsorptionโ€
3. N input โ–ถ๏ธŽ โ†‘ ureagenesis + โ†‘ urea (not โ†” to ๐Ÿ’ช๐Ÿฝ catabolism)
4. โ†‘UCR ๐ŸŸฐ exogenous N influx + prerenal dynamics (not AA use โŒ„ protein breakdown)
2. INCLUSION of these pxs in pooled ๐Ÿค“ wo_ stratification = conflating distinct MECHS + limits generalizability.
3. SOLUTIONS
1. Studies should:
1. PROSPECTIVELY **stratify**
1. cirrhosis
2. portal hypertension
2. UCR reported
2. โ™พ๏ธ assessment in **cirrhosis** โžฉ internationally validated approaches OVER CREA-only:
1. cystating C-based equations
2. measured CREA clearance

๐—ฉ๐—ฒ๐—ฟ ๐—บรก๐˜€ ๐—ฒ๐—ป: https://www.inaaqc.org/journal_reviews_2026"

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ---------------------------------๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ๐‚๐š๐ฌ๐ž๐‚๐š๐ซ๐ž๐Ÿ‘๐Ÿ”๐ŸŽ: ...
17/06/2026

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
---------------------------------
๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ
๐‚๐š๐ฌ๐ž๐‚๐š๐ซ๐ž๐Ÿ‘๐Ÿ”๐ŸŽ: ๐„๐ง๐ก๐š๐ง๐œ๐ข๐ง๐  ๐€๐’๐‚๐•๐ƒ ๐‚๐š๐ซ๐ž ๐“๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐ˆ๐ฆ๐ฆ๐ž๐ซ๐ฌ๐ข๐ฏ๐ž ๐‚๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐ƒ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง-๐Œ๐š๐ค๐ข๐ง๐ 
Established guidelines recommend aggressive lowering of LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) for optimal outcomes. However, substantial barriers hinder patientsโ€™ achievement of guideline-directed LDL-C targets, including patient adherence to treatment, gaps in provider knowledge, and failure to implement non-statin lipid-lowering therapies.


๐Ÿšฅ ๐—ฆ๐˜๐—ฎ๐—ฟ๐˜ ๐—ฎ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ถ๐˜๐˜†: https://www.healio.com/cme/primary-care/20250929/enhancing-ascvd-care-through-immersive-clinical-decision-making/overview?utm_source=SMC&utm_medium=email&utm_campaign=Template_Standard&utm_content=H512-HEA001
---------------------------------
โœ” ๐—˜ -๐—น๐—ฒ๐—ฎ๐—ฟ๐—ป๐—ถ๐—ป๐—ด: https://www.inaaqc.org/e-learning

๐๐ฅ๐จ๐จ๐ ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž ๐๐ฎ๐ซ๐ข๐ง๐  ๐ž๐ฑ๐ž๐ซ๐œ๐ข๐ฌ๐ž ๐ข๐ง ๐ซ๐ž๐ฅ๐š๐ญ๐ข๐จ๐ง ๐ญ๐จ ๐ฉ๐ก๐ฒ๐ฌ๐ข๐œ๐š๐ฅ ๐Ÿ๐ข๐ญ๐ง๐ž๐ฌ๐ฌ ๐š๐ง๐ ๐œ๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐จ๐ฎ๐ญ๐œ๐จ๐ฆ๐ž๐ฌ: ๐ญ๐ก๐ž ๐„๐—๐„๐‘๐“๐ˆ๐Ž๐ ๐ฌ๐ญ๐ฎ๐๐ฒ In concl...
16/06/2026

๐๐ฅ๐จ๐จ๐ ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž ๐๐ฎ๐ซ๐ข๐ง๐  ๐ž๐ฑ๐ž๐ซ๐œ๐ข๐ฌ๐ž ๐ข๐ง ๐ซ๐ž๐ฅ๐š๐ญ๐ข๐จ๐ง ๐ญ๐จ ๐ฉ๐ก๐ฒ๐ฌ๐ข๐œ๐š๐ฅ ๐Ÿ๐ข๐ญ๐ง๐ž๐ฌ๐ฌ ๐š๐ง๐ ๐œ๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐จ๐ฎ๐ญ๐œ๐จ๐ฆ๐ž๐ฌ: ๐ญ๐ก๐ž ๐„๐—๐„๐‘๐“๐ˆ๐Ž๐ ๐ฌ๐ญ๐ฎ๐๐ฒ
In conclusion, systolic blood pressure during exercise in relation to physical fitness is associated with an increased risk of cardiovascular events and could provide a clinically actionable marker to drive interventions aimed at reducing hypertension-related cardiovascular risk.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Schultz MG, Otahal P, Roberts-Thomson P, et al, Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study, European Heart Journal, 2026;, ehaf1082, https://doi.org/10.1093/eurheartj/ehaf1082
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

๐๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐๐ฎ๐ซ๐š๐ง๐ญ๐ž ๐ž๐ฅ ๐ž๐ฃ๐ž๐ซ๐œ๐ข๐œ๐ข๐จ ๐ž๐ง ๐ซ๐ž๐ฅ๐š๐œ๐ขรณ๐ง ๐œ๐จ๐ง ๐ฅ๐š ๐š๐ฉ๐ญ๐ข๐ญ๐ฎ๐ ๐Ÿรญ๐ฌ๐ข๐œ๐š ๐ฒ ๐ฅ๐จ๐ฌ ๐ซ๐ž๐ฌ๐ฎ๐ฅ๐ญ๐š๐๐จ๐ฌ ๐œ๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ๐ž๐ฌ: ๐ž๐ฅ ๐ž๐ฌ๐ญ๐ฎ๐๐ข๐จ ๐„๐—...
16/06/2026

๐๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐๐ฎ๐ซ๐š๐ง๐ญ๐ž ๐ž๐ฅ ๐ž๐ฃ๐ž๐ซ๐œ๐ข๐œ๐ข๐จ ๐ž๐ง ๐ซ๐ž๐ฅ๐š๐œ๐ขรณ๐ง ๐œ๐จ๐ง ๐ฅ๐š ๐š๐ฉ๐ญ๐ข๐ญ๐ฎ๐ ๐Ÿรญ๐ฌ๐ข๐œ๐š ๐ฒ ๐ฅ๐จ๐ฌ ๐ซ๐ž๐ฌ๐ฎ๐ฅ๐ญ๐š๐๐จ๐ฌ ๐œ๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ๐ž๐ฌ: ๐ž๐ฅ ๐ž๐ฌ๐ญ๐ฎ๐๐ข๐จ ๐„๐—๐„๐‘๐“๐ˆ๐Ž๐
En conclusiรณn, la presiรณn arterial sistรณlica durante el ejercicio en relaciรณn con la condiciรณn fรญsica se asocia con un mayor riesgo de eventos cardiovasculares y podrรญa proporcionar un marcador clรญnicamente procesable para impulsar una intervenciรณn dirigida a reducir el riesgo cardiovascular relacionado con la hipertensiรณn.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Schultz MG, Otahal P, Roberts-Thomson P, et al, Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study, European Heart Journal, 2026;, ehaf1082, https://doi.org/10.1093/eurheartj/ehaf1082
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

"๐—๐จ๐ฎ๐ซ๐ง๐š๐ฅ ๐—ฅ๐ž๐ฏ๐ข๐ž๐ฐ (๐‰๐‘)----------------------------------------------Performed on: Monday, April 23, 2026 ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐‚๐‚ - ๐‘๐ž๐œ๐จ๐ง๐ฌ๐ข...
16/06/2026

"๐—๐จ๐ฎ๐ซ๐ง๐š๐ฅ ๐—ฅ๐ž๐ฏ๐ข๐ž๐ฐ (๐‰๐‘)
----------------------------------------------
Performed on: Monday, April 23, 2026
๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐‚๐‚ - ๐‘๐ž๐œ๐จ๐ง๐ฌ๐ข๐๐ž๐ซ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฎ๐ซ๐ž๐š-๐ญ๐จ-๐œ๐ซ๐ž๐š๐ญ๐ข๐ง๐ข๐ง๐ž ๐ซ๐š๐ญ๐ข๐จ ๐š๐ฌ ๐š ๐ฌ๐ข๐ ๐ง๐š๐ฅ ๐จ๐Ÿ ๐ฆ๐ฎ๐ฌ๐œ๐ฅ๐ž ๐œ๐š๐ญ๐š๐›๐จ๐ฅ๐ข๐ฌ๐ฆ ๐ข๐ง ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐œ๐ข๐ซ๐ซ๐ก๐จ๐ฌ๐ข๐ฌ (๐Ž๐ฎ๐ฌ๐ฌ๐š๐ฅ๐š๐ก) (๐ฆ๐š).๐ฉ๐๐Ÿ

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ma โ–ถ๏ธŽ 2025, CC, FR โž– ma โž• Paulus et al. (MA, UTC CC 2025) โž• โ“
3. R โ–ถ๏ธŽ 2025, CC, NL โž– srMA โž• 47/1450 โž• Sep 3, 2024 โž– P I C O:
- **๐Ÿ…ฟ:** CI pxs
- ๐Ÿ…ธ: UCR value (at least 1)
- ๐Ÿ…ฒ: NA
- **๐Ÿ…พ:** pOC = protein catabolism
4. CAUTION. Cirrhosis โž• portal hypertension:
1. This type of admissions are frequent โžฉ 2-4,5% (national cohorts + sr)
2. In ICU ():
1. 20% = cirrhosis โžฉ decompensation + ACLD + variceal hemorrhages + HRS
2. 1/3 = CLD (high-dependency)
3. Both components of UCR are influenced by OTHER processes:
1. ureagenesis
2. sarcopenia
4. IF this subgroup is taken in the *pooled* ๐Ÿค“ โ†’ BIAS (inflatingโŒ„attenuating: โ†” ).
5. CREA issues
1. Cirrhosis โžฉ ๐Ÿ’ช๐Ÿฝ homeostasis
2. Sarcopenia:
1. 14-55% in cirrhosis
2. โ†”: โ†“ skeletal ๐Ÿ’ช๐Ÿฝ
3. CLD MECHS โžฉ โ†“ CREA (not โ†‘GFR)
1. imp โ—ธ creatine synthesis
2. โ†‘ fractional tubular secretion
3. underestimation in โ†‘bilirrubinemia
4. Combined effect โžฉ โ†“shift in CREA for any GFR
5. โˆ‘: โ†‘UCR in cirrhosis REFLECTS โ†“CREA production (not โ†‘ protein catabolism)

๐—ฉ๐—ฒ๐—ฟ ๐—บรก๐˜€ ๐—ฒ๐—ป: https://www.inaaqc.org/journal_reviews_2026"

๐ƒ๐€๐’๐‡-๐…๐จ๐จ๐ ๐๐š๐ญ๐ญ๐ž๐ซ๐ง๐ฌ ๐š๐ง๐ ๐“๐ก๐ž๐ข๐ซ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ ๐จ๐ง ๐๐ฅ๐จ๐จ๐ ๐๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž In conclusion, in this study, a home delivery program of DASH-sty...
13/06/2026

๐ƒ๐€๐’๐‡-๐…๐จ๐จ๐ ๐๐š๐ญ๐ญ๐ž๐ซ๐ง๐ฌ ๐š๐ง๐ ๐“๐ก๐ž๐ข๐ซ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ ๐จ๐ง ๐๐ฅ๐จ๐จ๐ ๐๐ซ๐ž๐ฌ๐ฌ๐ฎ๐ซ๐ž
In conclusion, in this study, a home delivery program of DASH-style foods, along with nutritional counseling, reduced blood pressure and LDL cholesterol levels beyond comparable monetary compensation. However, the effects were not sustained after the intervention ended.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Juraschek SP, Col H, Ferro K, et al. DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial. JAMA. Published
online November 09, 2025. doi:10.1001/jama. 2025.21112
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

๐€๐ฅ๐ข๐ฆ๐ž๐ง๐ญ๐จ๐ฌ ๐œ๐จ๐ง ๐ฉ๐š๐ญ๐ซรณ๐ง ๐ƒ๐€๐’๐‡ ๐ฒ ๐ฌ๐ฎ๐ฌ ๐ž๐Ÿ๐ž๐œ๐ญ๐จ๐ฌ ๐ž๐ง ๐ฅ๐š ๐ฉ๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ En conclusiรณn, en este estudio, un programa de entrega a ...
13/06/2026

๐€๐ฅ๐ข๐ฆ๐ž๐ง๐ญ๐จ๐ฌ ๐œ๐จ๐ง ๐ฉ๐š๐ญ๐ซรณ๐ง ๐ƒ๐€๐’๐‡ ๐ฒ ๐ฌ๐ฎ๐ฌ ๐ž๐Ÿ๐ž๐œ๐ญ๐จ๐ฌ ๐ž๐ง ๐ฅ๐š ๐ฉ๐ซ๐ž๐ฌ๐ขรณ๐ง ๐š๐ซ๐ญ๐ž๐ซ๐ข๐š๐ฅ
En conclusiรณn, en este estudio, un programa de entrega a domicilio de alimentos de estilo DASH, junto con asesoramiento nutricional, redujo la presiรณn arterial y los niveles de colesterol LDL mรกs allรก de una compensaciรณn monetaria comparable. Sin embargo, los efectos no se mantuvieron una vez finalizada la intervenciรณn.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Juraschek SP, Col H, Ferro K, et al. DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial. JAMA. Published
online November 09, 2025. doi:10.1001/jama. 2025.21112
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ---------------------------------๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ๐“๐‘๐Ž๐๐Ÿ ๐€๐ƒ๐‚๐ฌ ๐ข๐ง...
12/06/2026

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
---------------------------------
๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ
๐“๐‘๐Ž๐๐Ÿ ๐€๐ƒ๐‚๐ฌ ๐ข๐ง ๐๐ซ๐ž๐š๐ฌ๐ญ ๐‚๐š๐ง๐œ๐ž๐ซ: ๐”๐ฉ๐๐š๐ญ๐ž๐ฌ ๐จ๐ง ๐ญ๐ก๐ž ๐‹๐š๐ญ๐ž๐ฌ๐ญ ๐‚๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐“๐ซ๐ข๐š๐ฅ ๐ƒ๐š๐ญ๐š ๐š๐ง๐ ๐€๐„ ๐Œ๐š๐ง๐š๐ ๐ž๐ฆ๐ž๐ง๐ญ
Upon completion of this activity, participants should be able to:
โ€ข Analyze the latest clinical trial data for new and emerging TROP2-targeted ADCs for the treatment of mBC
โ€ข Apply clinical trial data and guideline recommendations when selecting patients with mBC to receive TROP2-targeted ADCs


๐Ÿšฅ ๐—ฆ๐˜๐—ฎ๐—ฟ๐˜ ๐—ฎ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ถ๐˜๐˜†: https://www.healio.com/cme/hematology-oncology/20250613/trop2-adcs-in-breast-cancer/overview?utm_source=SMC&utm_medium=email&utm_campaign=Template_Standard&utm_content=A621
---------------------------------
โœ” ๐—˜ -๐—น๐—ฒ๐—ฎ๐—ฟ๐—ป๐—ถ๐—ป๐—ด: https://www.inaaqc.org/e-learning

Adres

Route De Lennik 804
Brussels

Website

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Snelkoppelingen

Delen

Type